Blueprint Medicines Corp expected to post a loss of $1.29 a share - Earnings Preview

Blueprint Medicines

30/07/2024 19:57

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 1
for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 79.9% increase in revenue to $103.575 million from $57.57
million a year ago, according to the mean estimate from 17
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Blueprint Medicines Corp
is
for a loss of $1.29 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $125.00​, above​ its last closing price
of $110.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.65       -1.66      -1.32     Beat    20.6
 Dec. 31 2024  -2.06       -2.04      -1.82     Beat    10.8
 Sep. 30 2023  -2.33       -2.37      -2.20     Beat    7.1​
 Jun. 30 2023  -2.54       -2.54      -2.19     Beat    13.8
 ​​Mar.        -2.69       -2.67      -2.15     Beat    19.5
 31 2023                                                
 Dec. 31 2022  -2.65       -2.65      -2.65     Met     0​
 Sep. 30 2022  -2.46       -2.49      -2.23     Beat    10.3
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3
 This summary was machine generated July 30 at 18:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)